Furthermore, consistent with evidence implicating BAX/BAK interactions in MCL-1 stabilization in CLL cells,30 the finding that BAX/BAK knock-out cells were largely protected from the Src/MCL-1 inhibitor regimen strongly implicates these multi-domain proteins in potentiation of MCL-1 antagonist activity in AML cells by Src inhibition. The gene discussed is BAK1; the disease is B-cell chronic lymphocytic leukemia.